Silence Therapeutics Reports Halved Q1 Net Loss, Advances Key Clinical Programs
Summary
Silence Therapeutics plc announced first-quarter 2026 financial results showing a significant reduction in net loss and R&D expenses, alongside positive updates on its divesiran and SLN312 clinical programs.
Key Events
-
Reduced Net Loss
Net loss for Q1 2026 significantly improved to $15.0 million, down from $28.5 million in Q1 2025.
-
Lower R&D Expenses
Research and development expenses decreased substantially to $9.1 million from $20.8 million year-over-year, primarily due to the completion of zerlasiran Phase 3 readiness in 2025.
-
Clinical Pipeline Progress
The Phase 2 SANRECO trial for divesiran is on track for topline results in August 2026, and a Phase 1 abstract for SLN312 was accepted for a late-breaking oral presentation.
-
Cash Position
The company reported a cash, cash equivalents, and short-term investments balance of $70.1 million as of March 31, 2026.
Analysis
This 8-K filing provides a more optimistic outlook for Silence Therapeutics compared to its previous 2025 annual report, which detailed a doubled net loss and terminated collaborations. The company nearly halved its net loss in Q1 2026, primarily driven by a substantial reduction in R&D expenses. Additionally, the company highlighted progress in its pipeline, with Phase 2 topline results for divesiran expected in August 2026 and an abstract for SLN312 accepted for a late-breaking presentation. These developments suggest improved financial management and continued advancement of its core assets, which are crucial for a clinical-stage biotechnology company.
At the time of this filing, SLN was trading at $7.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $347.6M. The 52-week trading range was $3.54 to $8.40. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.